Clinical Features and Treatment Outcomes among Children with Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: A 20-Year Study in a Tertiary Referral Hospital

Table 1

Demographics of patients with Stevens-Johnson syndrome and overlap-toxic epidermal necrolysis.

	SJS, N = 20	Overlap-TEN, N = 16	Overall, N = 36	P value
Male (%)	8 (40.0)	8 (50.0)	16 (44.4)	0.549
Age (yr) (mean ± SD)	8.6 ± 4.2	9.9 ± 3.6	9.2 ± 4.0	0.373
Underlying diseases, N (%)				0.623
None	7 (35.0)	8 (50.0)	15 (41.6)
Neurological diseases	6 (30.0)	6 (37.5)	12 (33.3)
(seizure, MELAS, GBS)
HIV	2 (10.0)	1 (6.2)	3 (8.3)
ESRD	1 (5.0)	1 (6.2)	2 (5.6)
Wilson disease	2 (10.0)	0	2 (5.6)
SLE	1 (5.0)	0	1 (2.8)
Cyanotic heart disease	1 (5.0)	0	1 (2.8)
Probable causative factors (%)				0.185
Unknown	4 (20.0)	2 (12.5)	6 (16.6)
Infection	1 (5.0)	3 (18.8)	4 (11.1)
Drug	15 (75.0)	11 (68.7)	26 (72.3)
Antiepileptics	5 (25.0)	8 (50.0)	13 (36.1)
Antibiotics	7 (35.0)	2 (12.5)	9 (25.0)
D-penicillamine	2 (10.0)	0	2 (5.6)
Antivirus	1 (5.0)	1 (6.2)	1 (2.8)
NSAIDs	0	0	1 (2.8)

MELAS, mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke; GBS, Guillain-Barre syndrome; HIV, human immunodeficiency virus; ESRD, end-stage renal disease; SLE, systemic lupus erythematosus.